DocMorris Raises 2026 External Revenue Growth Forecast to 12.5% — 15%
DocMorris raised its 2026 external revenue growth forecast to 12.5%-15% from 9%-13%. Adjusted EBITDA is now forecast above minus CHF 10 million, versus a previous range of minus CHF 17.5 million to minus CHF 10 million. Third-quarter adjusted EBITDA reached CHF 600,000, achieving breakeven ahead of schedule; prescription medicine revenue growth accelerated to 78.3% in local currency. Capital expenditure guidance remains below CHF 30 million. * Management reaffirmed its target of reaching free cash flow breakeven during 2027; medium-term targets remain unchanged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DocMorris AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2416062_en) on October 15, 2026, and is solely responsible for the information contained therein. (C)
5%-15% from 9%-13%. 5 million to minus CHF 10 million. 3% in local currency. Capital expenditure guidance remains below CHF 30 million.
* Management reaffirmed its target of reaching free cash flow breakeven during 2027; medium-term targets remain unchanged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DocMorris AG published the original content used to generate this news brief via EQS News (Ref.
ID: adhoc_2416062_en) on October 15, 2026, and is solely responsible for the information contained therein. (C)